Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lecithin-bound iodine
- Development stage
- Unknown
- Lead developer
- Daiichi Sankyo
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
Lecithin-bound iodine (LBI), also known as Jolethin or iodolecithin, is a compound formed by the complexation of iodine with lecithin (phosphatidylcholine)[1][5]. It has been used clinically for its effects on thyroid function and in ophthalmology to enhance retinal metabolism and tissue respiration[2][4][7]. LBI is thought to exert anti-goitrous effects by delivering inorganic iodide in vivo, leading to suppression of thyroid ornithine decarboxylase activity and induction of apoptosis in thyroid tissue[7]. In ophthalmology, it has demonstrated protective effects on retinal pigment epithelial cells under hypoxic stress by maintaining tight junction integrity and reducing inflammatory cytokines[4]. The compound is also studied for potential benefits in cognitive health due to the combined properties of iodine (essential for thyroid hormone synthesis) and lecithin (a phospholipid important for cell membrane structure)[8].
- Brand names
- Jolethin
- Other names
- lecithin-bound iodineiodolecithinlecithin, iodide
02
Targets
TPO (Thyroid peroxidase)ODC1 (Ornithine decarboxylase)
Beyond the preview
Go deeper on lecithin-bound iodine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lecithin-bound iodine.